Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof

Patent metadata

Field	Value
Publication number	US-10975114-B2
Application number	US-201816609126-A
Country	US
Kind code	B2
Filing date	Apr 26, 2018
Priority date	Apr 28, 2017
Publication date	Apr 13, 2021
Grant date	Apr 13, 2021

Abstract

The present invention provides the cyclic dinucleotide compound 2′2′-RR-(3′F-A)(3′F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.

First claim

We claim:

1. A compound having the structure:

or a tautomer, pharmaceutically acceptable salt, pharmaceutically acceptable solvate or pharmaceutically acceptable hydrate thereof.

2. A composition comprising the compound according to claim (i) a pharmaceutically acceptable excipient; or (ii) a delivery vehicle which enhances cellular uptake and/or stability of the compound; or (iii) one or more agents selected from the group consisting of an immune checkpoint inhibitor; a Toll-like Receptor (TLR) agonist; a composition that mediates innate immune activation via TLRs, via (NOD)-like receptors (NLRs), via Retinoic acid inducible gene-based (RIG)-1-like receptors (RLRs), via C-type lectin receptors (CLRs), or via pathogen-associated molecular patterns (“P AMPs”); and a chemotherapeutic agent; or (iv) an inactivated tumor cell which expresses and secretes one or more cytokines which stimulate dendritic cell induction, recruitment and/or maturation, or one or more heat shock proteins.

3. The composition according to claim 2 , wherein the composition does not include an agent that enhances cellular permeability of the compound or an agent that enhances uptake of the compound into a cell.

4. The composition according to claim 2 , wherein the delivery vehicle comprises one or more agents selected from the group consisting of lipids, liposomes, hydrogels, interbilayer crosslinked multilamellar vesicles, biodegradable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.

5. The composition according to claim 2 , wherein the one or more agents is an immune checkpoint inhibitor, which is optionally selected from the group consisting of a CTLA-4 pathway antagonist, a PD-I pathway antagonist, a Tim-3 pathway antagonist, a Vista pathway antagonist, a BTLA pathway antagonist, a LAG-3 pathway antagonist, and a TIGIT pathway antagonist.

6. The composition according to claim 2 , wherein the one or more agents is a histone deacetylase inhibitor, which is optionally selected from the group consisting of panobinostat, vorinostat, romidepsin, chidamide, valproic acid, belinostat, pyroxamide, mocetinostat, abexinostat, entinostat, pracinostat, resminostat, givinostat, quisinostat, ricolinostat, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, and CG200745.

7. The composition according to claim 2 , wherein the inactivated tumor cell expresses and secretes one or more cytokines selected from the group consisting of GM-CSF, CCL20, CCL3, IL-12p70 and FLT-3 ligand.

8. The composition according to claim 2 , wherein the inactivated tumor cell expresses and secretes a gp96-Ig fusion protein.

9. A method for treating an individual suffering from cancer, comprising:
administering to the individual in need thereof an effective amount of the compound according to claim 1 .

10. The method according to claim 9 , wherein the cancer is selected from the group consisting of a colorectal cancer, an aero-digestive squamous cancer, a lung cancer, a brain cancer, a liver cancer, a stomach cancer, a bladder cancer, a thyroid cancer, an adrenal cancer, a gastrointestinal cancer, an oropharyngeal cancer, an esophageal cancer, a head and neck cancer, an ovarian cancer, a uterine cancer, a cervical cancer, an endometrial cancer, a breast cancer, a melanoma, a prostate cancer, a pancreatic carcinoma, a renal carcinoma, a sarcoma, a leukemia, a Merkel-cell carcinoma, a lymphoma and a multiple myeloma.

11. The method according to claim 9 , wherein the administration is intra-tumoral, peri-tumoral, or directly into the tumor-draining lymph node(s).

12. The method according to claim 9 , wherein the method further comprises administering one or more additional cancer therapies to the individual.

13. The method according to claim 12 , wherein the one or more additional cancer therapies comprise (i) radiation therapy, surgery, a chemotherapy, or an immunotherapy; or (ii) administering one or more therapeutic antibodies to the individual; or (iii) administering one or more checkpoint inhibitors to the individual; or (iv) administering an inactivated tumor cell that expresses and secretes one or more cytokines or one or more heat shock proteins to the individual.

14. The method according to claim 13 , wherein the immune checkpoint inhibitor(s) comprise an agent selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, an anti-TIM-3 antibody, an anti-BTLA antibody, an anti-Vista antibody, an anti-B7-H3 antibody, an anti-CD70 antibody, an anti-KIR antibody, and an anti-LAG-3 antibody.

15. The method according to claim 13 , wherein the inactivated tumor cell expresses and secretes one or more cytokines selected from the group consisting of GM-CSF, CCL20, CCL3, IL-12p70, and FLT-3 ligand.

16. The method according to claim 13 , wherein the inactivated tumor cell expresses and secretes a gp96-Ig fusion protein.

17. The method according to claim 12 , wherein the one or more additional cancer therapies comprises administering a histone deacetylase inhibitor to the individual, wherein the histone deacetylase inhibitor is selected from the group consisting of panobinostat, vorinostat, romidepsin, chidamide, valproic acid, belinostat, pyroxamide, mocetinostat, abexinostat, entinostat, pracinostat, resminostat, givinostat, quisinostat, ricolinostat, CUDC-101, AR-42, CHR-2845, CHR-3996, 4SC-202, and CG200745.

Assignees

• Aduro Biotech Inc
• Novartis Ag
• Chinook Therapeutics Inc

Inventors

• Leong Justin
• Ndubaku Chudi Obioma
• Mckenna Jeffrey

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• C07H21/02 Primary

  with ribosyl as saccharide radical · CPC title

• A61K2039/585

  wherein the target is cancer · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title